pepinemab + pembrolizumab
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Trial Timeline
Aug 9, 2021 → Jul 24, 2024
NCT ID
NCT04815720About pepinemab + pembrolizumab
pepinemab + pembrolizumab is a phase 1/2 stage product being developed by Merck for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC). The current trial status is completed. This product is registered under clinical trial identifier NCT04815720. Target conditions include Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC).
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04815720 | Phase 1/2 | Completed |
Competing Products
4 competing products in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug Combination Therapy | Sun Pharmaceutical | Phase 2 | 42 |
| MEDI4736 + Tremelimumab + MEDI4736 + Tremelimumab | AstraZeneca | Phase 2 | 35 |
| Pembrolizumab + Cisplatin + Carboplatin + Gemcitabine | Merck | Phase 2 | 42 |
| Nivolumab + Paclitaxel + Cetuximab + Paclitaxel | Bristol Myers Squibb | Phase 2 | 35 |